Types of Clinical Studies
To obtain approval from the Food and Drug Administration (FDA) or an equivalent agency outside the United States to market and sell a new drug or biologic product for use in humans, a series of clinical studies must be performed. These clinical studies exist in four phases. Each phase has specific and differing requirements for patient types, goals, inclusion/exclusion criteria, design features, and expected outcomes. Combined, they build the patient care database for safety and efficacy that hopefully will lead to product approval.
KeywordsGauche Disease Drug Development Process Heterogeneous Patient Population Central Institutional Review Board Adverse Event Database
Unable to display preview. Download preview PDF.
- 1.Phase 1 Clinical Trials. FDA Handbook. Accessed at http://www.fda.gov/cder/handbook/phase1.htm on February 12, 2005.
- 2.Phase 2 Clinical Trials. FDA Handbook. Accessed at http://www.fda.gov/cder/handbook/phase2.htm on February 12, 2005.
- 3.Phase 3 Clinical Trials. FDA Handbook. Accessed at http://www.fda.gov/cder/handbook/phase3.htm on February 12, 2005.
- 4.E6 Good Clinical Practice: Consolidated Guidance. ICH. April 1996. Accessed at http://www.fda.gov/cder/guidance/959fnl.pdf on February 12, 2005.
- 5.E10 Choice of Control Groups and Related Issues in Clinical Trials. ICH. May 2001. Accessed at http://www.fda.gov/cder/guidance/4155fnl.pdf on February 12, 2005.
- 6.Temple RJ. Active control non-inferiority studies: theory, assay sensitivity, choice of margin. February 10, 2002. Accessed at http://www.fda.gov/ohrms/dockets/ac/02/slides/3837s1_02_Temple/sld001.htm on February 12, 2005.
- 7.Center for Drug Evaluation and Research. Procedures for tracking and reviewing phase 4 commitment. Accessed at http://www.fda.gov/c der/mapp/6010–2.pdf on February 12, 2005.
- 8.Cramer JA, Spilker B. Quality of Life and Pharmacoeconomics: An Introduction. Philadelphia: Lippincott-Raven. 1997.Google Scholar
- 9.Balekdjian D, Russo M. Managed care mandate: show us the value. Pharmaceutical Executive 2003;23 (Special report).Google Scholar
- 10.Adapted from Venturini F, Johnson K. Introduction to Pharmacoeconomic Principles and Application in Pharmacy Practice. Can J Hosp Pharm 2002;55(2):.Google Scholar
- 11.Louie SG. How to conduct a pharmacoeconomics study. Educational monograph. USC School of Pharmacy. 2002.Google Scholar
- 12.ACCP–Pharmacoeconomics and Outcomes, Applications for Patient Care (Educational program, Module 1, 2, 3) American College of Clinical Pharmacy Kansas City, MO.Google Scholar
- 18.The value of providing quality-of-life information to managed care decision makers. Drug Benefit Trends 2001;13(7): 45–52.Google Scholar
- 20.Bernard S. The 5 myths of pharmacogenomics. Pharmaceutical Executive 2003;23(10):70–78.Google Scholar
- 23.Center for Drug Evaluation and Research. Pharmacogenomic data submission. November 2003. Accessed at http://www.fda.gov/cder/guidance/5900dft.doc on February 12, 2005.
- 24.Faich G, Stemhagen A. Epidemiology and drug development–a primer. DIA Forum 2004;40(3):32–34.Google Scholar
- 26.Food and Drug Administration. Challenge and opportunity on the critical path to new medical products. Accessed at http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html on February 12, 2005.